Does Levetiracetam Cause SIADH?
Yes, levetiracetam can cause SIADH, though it is a rare adverse effect. While not prominently featured in major guidelines or the FDA label, case reports and clinical experience confirm this association, and clinicians should monitor for hyponatremia in patients receiving this medication.
Evidence from Guidelines and Drug Labels
The 2019 American Geriatrics Society Beers Criteria 1 explicitly added tramadol to the list of drugs associated with hyponatremia or SIADH, but notably removed several chemotherapeutic agents from this list. However, levetiracetam is not specifically mentioned in this guideline update.
Multiple ESMO guidelines 2 consistently identify SIADH as occurring with "opioids, non-steroidal anti-inflammatory drugs (NSAIDs), anticonvulsants and antidepressants" 2. This broad categorization of anticonvulsants as SIADH-causing medications provides guideline-level support that levetiracetam, as an anticonvulsant, carries this risk.
The FDA drug label for levetiracetam 3 does not list SIADH or hyponatremia as a specific adverse effect in its comprehensive adverse event tables. The label documents hematologic abnormalities (minor decreases in RBC, hemoglobin, WBC, and neutrophils) but makes no mention of electrolyte disturbances or SIADH.
Clinical Evidence
A 2005 case report 4 documented hyponatremia associated with repeated use of levetiracetam in a patient predisposed to SIADH, demonstrating a clear temporal relationship with rechallenge. This represents direct clinical evidence of the association.
A comprehensive 2017 study 5 examining medication-induced SIADH in 198 hospitalized patients found that anticonvulsants were among the five drug classes implicated in 82.3% of drug-associated SIADH cases. While carbamazepine was specifically highlighted as commonly implicated, this study confirms anticonvulsants as a significant drug class for SIADH.
Clinical Implications and Monitoring
Monitor serum sodium levels in patients starting levetiracetam, particularly in those with:
- Pre-existing risk factors for SIADH (pulmonary disease, CNS pathology, malignancy)
- Concurrent use of other medications associated with SIADH (SSRIs, NSAIDs, opioids)
- Advanced age or multiple comorbidities
Key diagnostic criteria for SIADH 6, 2:
- Hyponatremia (serum sodium <134 mEq/L)
- Hypoosmolality (plasma osmolality <275 mOsm/kg)
- Inappropriately high urine osmolality (>500 mOsm/kg)
- Inappropriately high urinary sodium (>20 mEq/L)
- Clinical euvolemia
- Exclusion of hypothyroidism, adrenal insufficiency, and volume depletion
Management Approach
If SIADH develops with levetiracetam:
- Discontinue levetiracetam if clinically feasible and switch to an alternative anticonvulsant 2
- Implement fluid restriction (1-1.5 L/day) as first-line therapy 2, 7
- Ensure adequate oral salt intake 2
- For severe symptomatic hyponatremia (<120 mEq/L): consider hypertonic 3% saline 6
- For refractory cases: consider vaptans (tolvaptan, conivaptan) 8, 7
Important Caveats
- The incidence of levetiracetam-induced SIADH appears to be rare, as it is not listed in the FDA label despite extensive clinical trial data
- The 2024 ACEP seizure guidelines 9 recommend levetiracetam as a first-line agent for status epilepticus with no mention of SIADH concerns, suggesting the risk-benefit ratio remains favorable
- Levetiracetam is specifically recommended for seizure prophylaxis in CAR T-cell therapy patients 10 with minimal concern for adverse effects, further supporting its overall safety profile
The association exists but should not deter appropriate use of levetiracetam when clinically indicated. Simply maintain awareness and monitor sodium levels, particularly in high-risk patients.